William Blair analyst Myles Minter has maintained their bullish stance on BIIB stock, giving a Buy rating on October 28.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Myles Minter has given his Buy rating due to a combination of factors that highlight Biogen’s strong financial performance and strategic positioning. The company’s third-quarter revenues exceeded both the firm’s and consensus estimates, driven by robust sales in its multiple sclerosis (MS) franchise and the promising performance of Leqembi, despite some fluctuations in international sales. This indicates a solid revenue stream and potential for future growth.
Minter also notes that Biogen’s adjusted net income surpassed expectations, reflecting effective cost management and operational efficiency. Although there is a slight reduction in the company’s 2025 EPS guidance due to anticipated business development transactions, the overall financial health and strategic initiatives of Biogen suggest a positive outlook. These elements combined underpin Minter’s confidence in recommending a Buy rating for Biogen’s stock.
According to TipRanks, Minter is a 5-star analyst with an average return of 30.1% and a 61.69% success rate. Minter covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals, Biogen, and Argenx Se.
In another report released on October 28, Jefferies also maintained a Buy rating on the stock with a $190.00 price target.